BLAINTRAVENOUSINJECTABLEPriority Review
Approved
Aug 2024
Lifecycle
Growth
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
NIKTIMVO (axatilimab-csfr) by Incyte is colony stimulating factor receptor type 1 (csf-1r) inhibitors [moa]. Approved for colony stimulating factor-1 receptor blocker [epc]. First approved in 2024.
Drug data last refreshed Yesterday
Mechanism of Action
Colony Stimulating Factor Receptor Type 1 (CSF-1R) Inhibitors
Pharmacologic Class:
Colony Stimulating Factor-1 Receptor Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Company
Incyte
DE - Wilmington
Worked on NIKTIMVO at Incyte? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.